Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Immunome (Nasdaq: IMNM) deep dive: the FDA accepted the varegacestat NDA for desmoid tumors with an April 28, 2027 PDUFA date, backed by strong Phase 3 RINGSIDE data, 82.7M cash and a broader ADC pipeline.
Penguin Solutions has moved from the old SMART Global Holdings identity into a more focused AI infrastructure story. The market is no longer looking at PENG as a simple memory-cycle name. It is looking at a company trying to sit at the intersection of accelerated compute, advanced memory, AI cluster software, deployment services and enterprise-scale AI factory buildouts.
Biotech radar: Vertex to acquire Crinetics ($CRNX) for ~$10B, Seres ($MCRB) posts an early 80% Day 15 SER-155 signal in checkpoint-inhibitor enterocolitis, and OKYO ($OKYO) moves urcosimod to Phase 3 NEPTUNE after FDA Type D feedback.
Oil surged over 6% and energy stocks jumped after the U.S.-Iran framework broke down and Iranian oil sanctions returned. The Strait of Hormuz premium puts Chevron ($CVX), Exxon Mobil ($XOM) and Occidental ($OXY) back in focus.
The July cannabis trade is no longer about a simple “rescheduling soon” headline. It is about the administrative record being built inside the DEA hearing room: medical use, abuse potential, dependence profile, public-safety arguments, product-standardization attacks, impaired-driving concerns and the litigation path that may follow any final Schedule III decision.
Today’s radar is not built around one single theme. It is built around three very different biotech catalyst profiles: a small-cap GLP-1 implant narrative, a cleaner late-stage rare-disease regulatory story, and a highly speculative oncology microcap with a real but very early dosing question.
Deep dive on Trump Media ($DJT) after Q1 2026: $871K revenue, -$405.9M net loss driven by crypto marks, 9,542 BTC treasury, the CEO change, the paused Truth Social spin-off and the pending ~$6B TAE Technologies fusion merger.
Deep dive on the July 2026 AI infrastructure trade: TeraWulf's $19B Anthropic data-center lease, Broadcom's Apple custom-chip extension through 2031, and Micron's AI-driven memory super-cycle. $WULF, $AVGO, $MU.
Deep dive on Uranium Energy Corp. ($UEC): fiscal Q3 2026, U.S. ISR restart at Christensen Ranch and Burke Hollow, 1.456M lbs uranium inventory, $794M liquidity, no debt, Roughrider, UR&C conversion, catalysts and risks.
Deep dive on Lithium Americas ($LAC): Thacker Pass Phase 1 construction after Q1 2026, ~$1.2B cash, $2.93B capex, GM/DOE funding, dilution, lithium market risks, catalysts and red flags.
Biotech radar for July 6, 2026: Pharvaris ($PHVS) FDA NDA acceptance with an April 2027 PDUFA date, Agenus ($AGEN) three-year BOT+BAL survival data in MSS colorectal cancer, and Ionis ($IONS) Phase 3 pivotal enrollment complete in Angelman syndrome.
70+ biotech, small-cap, FDA and trading terms explained clearly: PDUFA date, CRL, cash runway, short squeeze, surrogate endpoint and more.
The cannabis trade is not waiting for a simple headline. It is watching an administrative record being built in real time. The key question is not only whether marijuana can move from Schedule I to Schedule III, but whether the evidence supporting that move is strong enough to survive opposition, procedural scrutiny and possible litigation.
Critical Metals Corp. ($CRML) is the starting point, but the full map reaches across MP Materials ($MP), USA Rare Earth ($USAR), Energy Fuels ($UUUU), NioCorp ($NB), Lithium Americas ($LAC), Albemarle ($ALB), Sigma Lithium ($SGML), Nouveau Monde Graphite ($NMG) and Westwater Resources ($WWR): heavy rare earths, lithium, graphite, niobium, scandium, magnet manufacturing, defense procurement, EV motors, wind turbines, robotics, electronics and the geopolitical race to rebuild strategic supply chains outside China.
Insider trading this week (June 29-July 3, 2026): the 20 biggest buys and 20 biggest sells by dollar value, with names, tickers, amounts and next catalysts.
Ten artificial-intelligence names, screened for momentum, chart position and base, with the genuine small/mid caps up top. For each one: a mini chart, a short explainer, the AI niche and the real analyst price targets with sources.
Watchlist 2026 · Defense & Defense-Tech Drones Space Counter-UAS Momentum AVAV · KTOS · RKLB · LUNR · PL · DRS · KRMN · RCAT · UMAC · ONDS Defense: the 10 hottest stocks of July 2026 Ten small and…
The junior developer aiming to bring the Neves hard-rock lithium project into production in Minas Gerais' "Lithium Valley": a fully paid processing plant already shipped to Brazil, offtake deals with Mitsui, Chengxin and Yahua — but also years of delays, heavy dilution and a CEO who controls 51% of the vote.
The microreactor developer aiming to become a fully integrated nuclear supply chain for the AI data-center era: pre-commercial technology, a large cash pile and a calendar of regulatory and test milestones.
MicroVision’s new Southeast Asia partnership adds another piece to a busy 2026 commercial reset, but the story remains a high-risk execution trade: stronger customer activity, broader LiDAR portfolio, still-small revenue, meaningful cash burn and visible financing risk.